Brand-New Biotech Poised to Explode in Value

Up 2%, then down 3%, then up 4% and then back down 2% more…

That’s the schizophrenic nature of today’s stock market. And no sector (reasonably or not) has been spared.

This includes the pot sector as well as many biotechs. Looking at the year-to-date chart for the iShares Nasdaq Biotech ETF, for example, we can see this painful action in plain view.

On the year IBB has given back almost all of its gains from Q1:


The drawdown in biotech is similarly illogical to the drawdown we’re seeing in pot stocks. I say illogical because many of the issues affecting the tech sector, retail, commodities and others do not affect biotechs.

Take No.1 market detractor Trump’s trade wars, for example. Many FDA-approved drugs are only sold here in the U.S., and those that are sold internationally are not on any tariff lists. So trade drama can’t affect most biotechs.

Additionally, we’re seeing major breakthroughs in many advanced biotech fields as well as some promising mergers that offered investors some nice flash profits this year.


Biotech Is STILL One of the Most Profitable Ways to Invest…

Investing in just a single biotech stock has the potential to yield explosive gains overnight.

But while biotech stocks can be the fastest moving, they can also be the most unpredictable.

Which is why you should never bet the farm on any one play… or invest more than you can afford to lose.

The BEST way to tap into this market — is with a proven expert by your side… someone who’s closed multiple triple-digit winners consistently…

That someone is, well, me!

With more than a decade of experience in the business, I’ve been able to pinpoint companies that have yielded over 10 times the money invested.

Take for instance our suggestions on Seattle Genetics (NASDAQ: SGEN) and Merck & Co. (NYSE: MRK) back in April of last year. Even after all the volatility and drawdowns in the sector… to date these stocks are both still up over 42% and 46%.

And our Inspire Medical Systems (NYSE: INSP) play, first suggested back in June of last year, is up over 80% as of today.

The long and short of it is that when you have good advice from folks like me, you can score big money no matter the market conditions.

Speaking of opportunity in biotech…

The Genetic Code

Obviously, different cell types use different combinations of genes. We’ve learned a lot about how this happens…

When cells develop, they respond to external signals that help determine what parts of the DNA to open up for activation. This controls what fate is assigned to a cell — whether it’s a skin cell or a bone cell or some other type of cell.

There is another layer on top of the genetics contained by the DNA. This layer, studied in epigenetics, determines the activity of the genes and therefore how cells behave.

Epigenetics doesn’t just help regulate how cells develop into their final states — it regulates them for their entire lives. Meaning cells can change behavior in response to their environment.

Epigenetic mechanisms can act like an accelerator and brake pedal for cells, turning up some genes and turning down others in response to change.

In some disease states, epigenetics results in some genes being turned on that are better turned off and vice versa. This makes the field of epigenetics ripe for new therapies and exciting medical discoveries worthy of big gains.

But more importantly, you could very well open the door to unlimited wealth with this groundbreaking biotech and its potentially lifesaving indication…

Longtime readers have already had the chance to profit off this new biotech trend.

Last October we suggested taking a swing on a company called Epizyme (NASDAQ: EPZM).


Epizyme is a leading epigenetics company tackling some of our biggest health problems, specifically Hodgkin lymphoma and other cancers.

As for the stock, shares are up over 40% since October. With a new therapy currently awaiting Phase 3 testing, this stock could be poised for another run-up pending any new FDA approvals.

More on Epizyme to come soon.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily

You May Also Be Interested In:

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco